A Drug Interaction Study With Fluticasone Furoate/GW642444 Inhalation Powder and Ketoconazole
Status:
Completed
Trial end date:
2010-08-28
Target enrollment:
Participant gender:
Summary
A randomized two-way crossover study to determine whether concomitant administration of CYP
P450 3A4 inhibitor ketoconazole and fluticasone furoate/GW642444M combination significantly
increases the systemic effects and exposure to repeat dose fluticasone furoate and/or
GW642444 in healthy subjects. Key assessments will include blood potassium, heart rate, blood
pressure, QTc, serum cortisol and pharmacokinetic parameters, and safety including vital
signs, ECGs, adverse event monitoring and laboratory safety tests, including blood glucose.